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Abstract: Imaging and laboratory biomarkers are an essential support to modern practice of medicine, allowing a better 
identification, severity titration, staging and follow-up of atherosclerosis and heart failure disease. This review provides an 
overview of imaging, biochemical and genetic biomarkers used in clinical practice and for research purposes in order to 
evaluate the 4 different aspect of patient vulnerability to cardiovascular disease: arterial; blood; myocardial; metabolic 
vulnerability. 
Yet, no single perfect biomarker exists and there is wide room for optimization and integration between clinical evalua-
tion and biomarker evaluation. In general, a targeted approach tailored on the individual patient should be preferred to a 
carpet diagnostic bombing, which will lead to an exorbitant multiplier of costs, risks and inappropriate testing.  
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INTRODUCTION 
 In 2001, a National Institute of Health working group 
standardized the definition of a biomarker as “a characteris-
tic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathological processes, or 
pharmacological responses to therapeutic interventions” [1]. 
The desirable properties of biomarkers vary with their in-
tended use. Proper biomarkers can be used in therapeutic 
trials as indicators or substitutes for clinically meaningful 
endpoints. They can serve as surrogate clinical endpoints and 
provide a direct measure of how the patient feels, functions 
or survives and can predict the effects of a therapy. Bio-
markers can replace distal clinical endpoints with more 
proximal ones that can be measured earlier, more frequently 
and with higher precision. Biomarkers may require reduced 
sample sizes and allow for faster decision making in incor-
porating or eliminating newer therapeutic approaches. Re-
gardless of the purpose for its use, a new biomarker will be 
of clinical value only if it is accurate, it is reproducibly ob-
tained in a standardized fashion, it is acceptable to the pa-
tient, it is easy to interpret by clinicians, it has high sensitiv-
ity and specificity for the outcome it is expected to identify, 
and there are data to suggest that knowledge of biomarkers 
levels changes management [2]. Many biomarkers in cardio-
vascular disease fulfil these desirable properties, and are 
therefore used in clinical practice and suitable candidates in 
cardiovascular clinical trials. They can be distinguished into 
imaging, biochemical (laboratory) and genetic biomarkers. 
Examples of imaging biomarkers include the degree of left 
ventricular dysfunction in heart failure, the carotid plaque 
burden in atherosclerosis, the extent and severity of stress-
induced myocardial ischemia in coronary artery disease [2]. 
Examples of laboratory biomarkers include the NT-proBNP  
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and troponin, established clinical markers of heart failure 
and myocardial tissue damage respectively.  
 Regarding genetic biomarkers, common genetic poly-
morphisms (Factor V Leiden and 20210G>A prothrombin 
mutations) are currently example of genetic factors used into 
clinical practice for screening the risk for thrombosis [3]. 
 The variety of new biomarkers, the rapid evolution in the 
field, the uncertainty about the role of the new technology 
and insecurity regarding the current standard in the area led 
to substantial controversy over which biomarker should be 
used, in which patient, and when. It is also unclear if there is 
a synergistic rather than antagonistic role of the 2 types of 
biomarkers. The potential usefulness of such synergism is 
highlighted by the current and rumoured future acquisition of 
several biomarker companies by major imaging companies 
[4]. On the other side, there are clear risks that this marketing 
driven synergism may multiply the already worrisome high 
levels of inappropriateness in the field of imaging and labo-
ratory testing [3,5-9]. The roadmap to validation of biomark-
ers follows 4 regulatory steps: stage 1 (“promising” pre-
biomarkers) or 2 (“developing” biomarker, with known ac-
curacy and reproducibility under highly controlled condi-
tions) to either one of 2 possible destinies: dismissal-
downgrading (which will limit/close further clinical use re-
ducing costs and development time) or upgrading to fully 
exploitable stage 3 (“developed” biomarker with established 
value added in a given clinical setting) or 4, i.e. “validated 
gatekeeper” required and/or accepted to assure safety and/or 
efficacy of an approved/licensed therapeutic intervention [1]: 
(Fig. 1). Only a low percentage of imaging candidates enter-
ing the biomarker development process will eventually sur-
vive to the extensive medical and research application stage. 
Examples of markers, which never reached the role of gate-
keeper – in spite of promising early results – are the use of 
echocardiography predictors in identifying responders to 
cardiac resynchronisation therapy on the basis of mechanical 
dyssynchrony [10] or myocardial perfusion contrast echo-
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cardiography for detection of coronary artery disease [11]. 
However, an impulse to this field is expected from the gen-
eral interest -shared by academia, pharma industry and major 
regulatory bodies- to promote the qualification of molecular 
imaging as a biomarker in drug developmen,t in response to 
the relevant attrition and diverging costs emerged in the 
pipeline of new medicine discovery and validation [e.g. http: 
//imi.europa.eu/index_en.html; http: //www.fda.gov/oc/initia 
tives/criticalpath/]. 
 Clinicians, scientists and the industry need an early and 
accurate identification of imaging and laboratory biomarkers 
of proved medical value and methodological robustness. The 
seed of efficacy under controlled clinical conditions should 
not be mistaken for the fruit of effectiveness, i.e. the value of 
the technique when deployed in the field [12]. 
THE PATHOPHYSIOLOGICAL TARGETS OF BIO-
MARKERS IN CARDIOVASCULAR DISEASE 
 The different biomarkers focus on different aspect of 
patient vulnerability to cardiovascular disease: arterial; 
blood; myocardial; metabolic vulnerability. All 4 vulner-
abilities concur to the clinical expression of atherosclerotic 
disease and heart failure, which may occur as a consequence 
of and independently from atherosclerotic disease (Fig. 2). 
 Acute coronary syndromes are accompanied by progres-
sive mechanical obstruction, dynamic obstruction, and 
plaque inflammation, instability, and rupture, followed by 
superimposed thrombosis – which is also determined by the 
pro-thrombotic tendency of blood: the “vulnerable blood”. 
Imaging can help marginally in the identification of low flow 
states, for instance by spontaneous echocontrast by TTE or 
reduced left atrial appendage flow velocity by Doppler TEE 
during atrial fibrillation, which identify a high risk of im-
pending thrombosis [13]. Once plaque-superimposed throm-
bosis occurs, it may be manifest as elevation of circulating 
D-dimer, plasminogen activator inhibitor-1 and von-Wille- 
brand factor.  
 The vulnerable myocardium can be identified through 
structural or functional markers. Among structural markers, 
left ventricular hypertrophy or left ventricular concentric 
remodelling (with normal left ventricular mass) can be best 
identified with real time 3D echocardiography [14]. Func-
tional markers are based on stress-induced perfusion (or 
coronary flow reserve) abnormalities, mirroring a coronary 
microvascular abnormality which may identify early stages 
of incipient cardiomyopathy, even with normal coronary 
arteries [15]. At a more advanced stage of disease, myocar-
dial vulnerability can be identified as left ventricular dys-
function (by ultrasound, CMR, CT or nuclear scans). 
 Arterial vulnerability can be tracked again with func-
tional markers (such as endothelial dysfunction evaluated 
with brachial artery reactivity testing or by myocardial PET 
imaging, the latter directly measuring coronary responses in 
a quantitative fashion and structural markers (such as carotid 
intima-media thickness by ultrasound and coronary artery 
calcium by CT) [16-18].  
 An additional, emerging dimension is the metabolic vul-
nerability. Along the traditional risk factors such as total 
cholesterol, LDL-C, low HDL, and glycemia, recently new 
factors were put forward such as gamma-GT [19], adi-
ponectin, leptin [20], and fT3 [21]. Laboratory biomarkers 
are more informative than bioimaging markers in identifying 
metabolic vulnerability. The possibility of imaging visceral 
fat (by CMR, CT or – to some extent – ultrasound) is how-
ever a novel, exciting perspective [22]. 
ATHEROSCLEROSIS CASCADE  
 The research interest and potentially appropriate clinical 
application of biomarkers are best framed within the current 
understanding of the pathobiology of atherosclerosis and 
heart failure. For atherosclerosis (Fig. 3), endothelial dys-
function (a functional imaging marker of arterial vulnerabil-
ity) or pre-intrusive atherosclerosis (a structural imaging 
marker, commonly detected as increased carotid intima-
media thickness) may progress over decades to impairment 
in coronary flow reserve, and only later to stress-induced 
dysfunction and eventually to less reversible stress-induced 
dysfunction at rest [23].  
 The time period preceding the onset of an acute coronary 
syndrome is characterized by atherosclerotic arterial lesions 
prone to rupture. Such lesions are rich in macrophages 
(which release lytic enzymes like metalloproteinases) and are 
associated with a reduction in smooth muscle cells, increase 
in lipids, and a thin fibrous cap [24]. These biochemical 
characteristics of vulnerable plaques are major targets for the 
development of specific tracers based on peptides for the 
detection of vascular remodelling [25,26] and glucose me-
tabolism for inflammation assessment, due to the avidity of 
macrophages for this substrate[27,28]. Acute coronary syn-
dromes are accompanied by progressive mechanical dys-
 
 
 
 
 
 
Fig. (1). The natural history of a biomarker, from the seed of efficacy to the fruit of effectiveness. 
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function, dynamic obstruction, and plaque inflammation, 
instability, and rupture, followed by superimposed thrombo-
sis. Superimposed thrombosis may be manifest as elevations 
of circulating D-dimer, plasminogen activator inhibitor 1, 
and von Willebrand factor. Ischemia is antedated by release 
of ischemia-modified albumin by a few hours and the devel-
opment of myocardial necrosis by time-dependent release of 
myocytes components such as troponins [29]. The hemody-
namic consequences of ischemia and/or infarction are re-
flected by elevation of plasma natriuretic peptide levels. It is 
therefore obvious that there is no “one marker fits all” ap-
proach, but rather the targeted marker tailored in a given 
patient in a certain clinical theatre: emergency department, 
physician’s office, coronary care unit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). The vulnerable milieu of the cardiovascular patient. For each of the 4 vulnerabilities, some commonly employed bioimaging (bold) 
and biochemistry markers are shown.  
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The atherosclerosis cascade. 
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 The functional stage of coronary endothelial dysfunction 
is at present best characterized by pharmacological vasodila-
tion, and this can be quantitatively assessed by myocardial 
PET imaging [18]. A simpler and more accessible, indirect 
index is represented by flow-mediated dilation of brachial 
artery by ultrasound, even though peripheral and coronary 
responses do not always correlate. 
 The functional stage of endothelial dysfunction is at pre-
sent best characterized by flow mediated dilation of brachial 
artery by ultrasound. There is uncertainty regarding the clini-
cal role of coronary calcium score by CT. Early, asympto-
matic atherosclerosis has a skeleton in its closet, and the 
amount of coronary calcium correlates moderately closely to 
the overall atherosclerotic plaque burden, but its place in risk 
stratification of asymptomatic individuals remains uncertain. 
It is true that the use of calcium score has quite convincing 
(non randomized) outcome impact over years [30], but it is 
equally true that the open question remains on how much 
incremental information can be obtained by CT angio [31]. It 
is also unclear if the extra-information provided by calcium 
score assessment is better than the one provided by simpler, 
radiation-free atherosclerosis imaging biomarkers such as 
carotid intima-media thickness by ultrasound scan [32]. Re-
cent guidelines do not recommend unselected “screening” or 
patient self-referral in individuals with very low (<1.0% an-
nual risk) or very high risk (>2% annual risk). A beneficial 
contribution can most likely be expected in individuals who 
seem to be at intermediate risk for coronary events (1.0-2.0% 
annual risk), yet this hypothesis has not been prospectively 
studied so far [33].  
 The real disruptive technology appeared in the last 5 
years is multi-slice CTA. The information content of CTA is 
very high, in any case higher than invasive angiography, 
probably equivalent to gray scale intravascular ultrasound 
plus angiography. Invasive coronary angiography can iden-
tify obstructive as well as complex lesions, but it is restricted 
to the coronary lumen and is unable to visualize the coronary 
wall. Thus, features as vessel remodelling or plaque compo-
sition are missed. CTA depicts not only a coronary lumi-
nogram as coronary angiography does, but also the thickness 
of the wall and the plaque composition to some extent [34] 
as ultrasound does [35,36]. This is especially important in 
the early diagnosis of coronary artery disease, since the ear-
liest stage of atherosclerosis is the initial positive remodel-
ling with preserved lumen, as plaque accumulates [37] (Fig. 
1). Several studies showed an increased level of inflamma-
tory markers, high lipid cores and pronounced medial thin-
ning in positively remodelled vessels [38]. Some of the ini-
tial acute presentations of the disease may occur when the 
adaptive remodelling mechanisms are exhausted and a 
threshold mass of plaque (depending on vessel diameter) 
starts to breach towards the lumen. CTA can also offer an 
insight on plaque structural composition which – for any 
given plaque size – contribute to plaque vulnerability [10], 
with lipid rich, high-risk plaques (hypoechoic by ultrasound 
and hypodense by CT), more prone to rupture and subse-
quent thrombotic occlusion than calcium rich, low-risk 
plaques (hyperechoic with shadowing by ultrasound and 
hyperdense by CT). There is growing evidence that hybrid 
imaging by PET (coronary flow reserve) and CTA may pro-
vide a more conclusive evaluation, especially in medium risk 
patients [39]. However, the main constraint of CTA and 
PET-CTA is exposure to ionizing radiation [40] that limits 
any screening application policy [41,42]. The forthcoming 
perspective [43] of hybrid PET-MRI and the increasing sen-
sitivity of PET scanners may change to some extent this as-
pect.  
HEART FAILURE CASCADE 
 The ageing of the population combined with the im-
proved post-infarction survival has rapidly increased the 
number of patients with heart failure with a prevalence esti-
mated as much as 1-2 % of the general population that rises 
to 10% in the elderly (Fig. 4). 
 In formulating the 2001 document, ACC/AHA guidelines 
developed a new approach – also endorsed in the 2005 
document – to the classification of heart failure, identifying 4 
stages [44]: stage A (at high risk, but without structural heart 
disease, e.g. hypertension); stage B (structural heart disease 
but without signs and symptoms of heart failure, e.g. previ-
ous myocardial infarction or asymptomatic valvular heart 
disease); stage C (structural heart disease with current or 
prior symptoms of heart failure) and stage D (refractory heart 
failure requiring specialized interventions). According to this 
staging approach, that is conceptually similar to that achi- 
eved by staging in other diseases such as cancer, patients 
would be expected to either not advance at all or to advance 
from one stage to the next, unless progression of the disease 
was slowed or stopped by treatment. Structural changes in 
Stage B heart failure patients may involve the assessment of 
cardiac remodelling and hypertrophy as well as myocardial 
fibrosis. Left ventricular hypertrophy and left ventricular 
remodelling are best studied with real time 3-D echocardi-
ography, more accurate and reproducible, as well as less time 
consuming, than 2D echo. CMR can provide – at a higher 
cost – an equally reliable information, and has also the 
unique capability to provide an accurate estimate of the pres-
ence, transmural extent, and severity of myocardial fibrosis 
with delayed enhancement protocols [45]. Among biochem-
istry markers, matrix metalloproteinase and their counter-
regulatory inhibitors have been studied with promising re-
sults. In presence of congestive heart failure, natriuretic pep-
tides have a major role. They can be helpful in distinguishing 
heart failure from other causes of dyspnoea [46]. Increases in 
cardiac natriuretic peptides and of biomarkers of cardiac 
imaging can also define higher and lower risk subsets of pa-
tients with heart failure [47,48]. 
GENETIC MARKERS: AT THE SOURCE OF THE 
CASCADE  
 Recent advances in genomic, proteomics and other "om-
ics" fields promise the discovery of new biomarkers raising 
the perspective of “personalised medicine”. 
 Genomics-based diagnostics will be incorporated into 
clinical practice, and they are used to diagnose, predict dis-
ease onset or recurrence, tailor treatment options, and assess 
treatment response. 
 Genetic biomarkers are defined as variants in the DNA 
code that alone or in combination are associated with disease 
expression, disease susceptibility, and disease outcome, in-
cluding therapeutic response. Some genetic findings are be-
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ginning to play an important role in the cardiovascular medi-
cine. 
 For instance, significant advances have been made in 
recent years in identifying the genetic basis of a variety of 
monogenic cardiovascular diseases, including familial car-
diomyopathies [49-52]. 
 Subsequently, genetic tests have been developed for the 
major mutations responsible for the disease and are used to 
confirm the diagnosis and to screen potentially affected rela-
tives. 
 Uniformly, inherited cardiomyopathies are characterized 
by a marked phenotypic and genetic heterogeneity, with in-
complete and age-dependent penetrance. Genotype-pheno- 
type relations are complex and not yet completely under-
stood. Over 700 mutations in 11 genes encoding contractile 
proteins of the cardiac sarcomere have been associated with 
hypertrophic cardiomyopathy (HCM).  
 Routine, extensive, clinical DNA testing is, at present. 
impractical because it is costly and time-consuming, but 
some features, such as ventricular septum morphology, elec-
trocardiogram parameters, and additional clinical parameters 
can help target DNA analysis of specific genes. [51,52]. For 
practical purposes, clinical testing is generally performed on 
the 3 most frequently involved sarcomere genes (-myosin 
heavy-chain, MYH7; myosin-binding protein C, MYBPC; 
and cardiac troponin T,TNNT2), estimated to account for 
about 60% of all familial clinically overt HCM forms.  
 Familial dilated cardiomyopathy (DCM) is also charac-
terized by high genetic heterogeneity as mutations in >20 
genes have been associated with the disease [49-52]. Despite 
the high number of disease genes, lamin A/C (LMNA) gene 
mutations (~30-40 % of cases) are the most frequent cause of 
familial DCM cases with cardiac conduction disorders, and 
they are correlated with a worse prognosis, particularly of 
sudden cardiac death and ventricular arrhythmias [51-53]. 
Therefore, genetic testing for LMNA in DCM patients and 
families is recommended for preventing fatal events. It is 
expected that ongoing genetic studies in validating the geno-
type–phenotype correlations will increase the clinical use of 
genetic markers in order to improve the clinical management 
of affected patients as well as to help the screening of family 
members. 
 However, the greatest promise and power of genomics-
based diagnostics is to identify a relevant set of causative 
genes for common multigenic disorders, such as atheroscle-
rosis and heart failure.  
 In these types of disorders, the inherent genetic compo-
nent mainly result from a single nucleotide polymorphisms 
(SNPs) in the gene that can affect the concentration or the 
function of the resulting translated protein. Specific SNPs 
may determine an individual’s susceptibility to disease de-
velopment and progression and/or the potential response to 
drug treatments.  
 Factor V Leiden (R506Q) and prothrombin (20210G>A) 
mutations provide the best example of how genetic biomark-
ers may be put into practice in the next future [9]. 
 With advances in technology and additional knowledge, 
other SNP testing will soon become a routine part of clinical 
practice.  
 In actual fact, SNPs on chromosome 9, that have been 
consistently shown to be associated with atherosclerosis de-
velopment and progression, may represent the most promis-
ing genetic markers to predict the individual cardiovascular 
risk [54].  
 Functional genetic variants can be responsible for imag-
ing alterations. There are also examples of gene variants that 
affect the imaging phenotype under stress condition. For 
instance, Arg389Gly polymorphism of 1- adrenoreceptors 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). The heart failure cascade. First row: the structural imaging markers; second row: the functional imaging markers. 
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affect the contractile response detectable by dobutamine 
stress echo: homozygous Arg389-1 AR subjects exhibited 
larger inotropic and blood pressure responses than subjects 
carrying one or two Gly389 alleles. [55].  
 Other studies have reported that family screening of pul-
monary artery systolic pressure (PASP) response to exercise 
may lead to an earlier diagnosis and more effective therapy 
for familial form of primary pulmonary hypertension (PPH). 
In fact, it has been observed that asymptomatic carriers of 
bone morphogenetic
 
protein receptor type-2 (BMPR2) gene 
mutation in families with heritable PPH may show an ab-
normal increase in pulmonary artery systolic pressure during 
exercise stress echocardiography [456]: (Fig. 5).  
OPEN ISSUES 1: COSTS AND RISKS OF BIOMARK-
ERS  
 Barriers to introducing new test are not restricted to lack 
of evidence of efficacy. Safety, tolerability, difficulty in per-
forming the exam and finally cost are important determinants 
in the choice of the biomarker in the clinical practice.  
 One of the prerequisites for the clinical use of biomarkers 
is demonstration of cost-effectiveness and risk-effectiveness. 
In fact, different biomarkers have different costs and some of 
them are not without risks. The cost of different imaging 
techniques is listed in Fig. (6) [57]. It is shown that PET can 
be equally, or even more, accurate than SPECT, but its clini-
cal use is limited by relatively high costs and complexity. 
Similarly, CAC score or – mostly – noninvasive coronary 
angiography by CT are fascinating techniques, but their use 
as screening procedures has been slowed by radiation dose 
and associated long-term risks (Fig. 7) [58]. Cost considera-
tions should also be considered for laboratory biomarkers. 
Although some evidence has been collected for instance with 
BNP in acute dyspnoea [59] and troponin in acute chest pain 
[60] in the emergency setting, usually information on cost is 
conspicuously lacking in scientific publication and clinical 
prescription patterns. In the use of one biomarker over the 
other, the cost of complementary or competing techniques 
should be considered. For instance, based on 2004 Medicare 
reimbursement data, each BNP test costs less than one eighth 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). An example of genetic imaging: exercise stress echo in carriers of abnormal genes of pulmonary hypertension in the pre-clinical, 
asymptomatic phase. Abnormal response of PASP to exercise in gene carriers. All family members with exercise-induced pulmonary hyper-
tension (AR group, right) were carriers of the disease-associated mutation. In contrast, only 2 of the 27 members (black lines, filled squares) 
with normal PASP response to exercise (NR group, left) had the disease-associated mutation. Resting PASPs were normal in both groups 
(mean PASP, 23.3±4 mm Hg vs 24±4 mm Hg in abnormal response vs normal response members, respectively; P=0.57). PASP estimated by 
Doppler echocardiography was significantly different between abnormal and normal response members during supine bicycle exercise. 
Modified by ref. [56]. 
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as much as a Doppler echo examination. The clinician should 
also consider, however, that the information of an imaging 
test such a resting echocardiogram extends well beyond the 
ruling out of a cardiac origin of dyspnoea, and includes 
unique data on left ventricular structure, function, valvular 
disease, pericardium, aorta, right ventricle, and pulmonary 
hemodynamics, and now extravascular lung water [61] – 
which most directly helps in identifying the cause of dyspnea 
[62]. 
 Other considerations should also be accounted for labora-
tory biomarkers. New tests, like the measurement of adi-
ponectin or IL6, are often not standardized and not designed 
for routine analyses. For this reason, they are also very ex-
pensive with the price dependent on the type of assay used 
for the measurements. At current, these tests are offered only 
in research facilities and not available for routine analyses. 
Recently, traditional routine laboratory exams, like GGT and 
urinary albumin, were considered among the biomarkers for 
CVD risk [63, 64]  
 However, the risk increment captured by elevated levels 
of new markers is modest, and little improvement is seen in 
traditional measures of discrimination such as the C statistic 
or the area under the receiver- operating-characteristic curve. 
[65]. 
 As regard genetic markers, they basically differ from 
other chemical biomarkers. Genetic tests remain generally 
expensive technologies that are labour-intensive and time-
consuming. 
 Costs of genetic tests may vary considerably (from sev-
eral hundreds to thousands Euro ) depending on the number 
of genes and nucleotides examined. For testing gene the first 
family member, sequencing gene now cost on the order of 
1500-4000. If a mutation is identified, other family mem-
bers may be offered confirmatory testing at a reduced rate 
that is around 250.  
 On the other hand, there is considerable debate over the 
new ‘‘predictive medicine’’ that could generate serious ethi-
cal, social and psychological consequences. Receiving ge-
netic risk information may, therefore, be more harmful than 
positive by raising unnecessary anxieties and providing a 
real prospect of discrimination based on a person’s genetic 
make-up [9]. 
 Therefore, genetic testing is not appropriate for every 
patients, but it should be used in selected cases, such as pa-
tients with an established family history of cardiomyopathy 
in 2 closely related relatives or in at-risk patients, when 
effectively can provide useful information for clinical man-
agement.  
OPEN ISSUES 2: THE MULTIMARKER APPROACH  
 Information experts know very well that too much infor-
mation can be equally uninformative as lack of information. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Estimated average costs of common cardiac imaging procedures when compared to 2D echocardiography. Modified by ref. 57 
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Areas for redundancies, contraindications, mistakes, and – in 
a word – noise are magnified as the number of sources of 
information increase. Many markers do explore basically the 
same aspect of vulnerability and the same stage of disease. 
For instance, inflammation plays a pivotal role in athero-
genesis, rapid coronary artery disease progression, plaque 
disruption and the acute clinical manifestation that result 
from intracoronary thrombus formation [66]. The most ex-
tensively investigated and accessible inflammatory marker 
for clinical use is CRP, which shows conclusively demon-
strated prognostic implications in patients with acute coro-
nary syndromes, stable coronary disease, and even in appar-
ently healthy men and women in whom CRP is an independ-
ent predictor of risk for myocardial infarction and stroke 
[67]. Other proposed inflammatory markers include neopro-
tein, cytokines, adhesion molecules, white blood cell count, 
CD40L, E-selection, Von Willebrand factor, pregnancy-
associated plasma protein A, lipoprotein associate phos-
phorilase A2, and neutrophil myeloperoxidase [2,67]. Simi-
lar conceptual overlap is present for markers of plaque rup-
ture (sCD40L, PIGF, PAPP-A, VCHM), thrombosis (PAI-1, 
sCD40L, VnF, D-dimer), ischemia (ischemia-modified al-
bumin, free fatty acids, choline), necrosis (troponin T, tro-
ponin I, CK-MB, myoglobin) and son on. The picture is 
likely to be further complicated by the advent of “omic” 
markers and the incorporation of bioimaging data in the 
theoretically sound “multi-marker approach” based on the 
statistical analysis of several biomarkers together. An “inde-
pendent risk factor” should be defined as a biomarker that 
retains its statistical association with the outcome when other 
established risk factors (predictors) for the outcome are in-
cluded in the model – but cardiovascular biomarkers are of-
ten correlated to each other. The mind-set “more is better” 
approach produces surprisingly little clinical and prognostic 
incremental benefits. We need robust statistical models im-
proved by the bioengineering of complexity (coping with 
uncertainties) to produce simple tools for the busy clinician 
[68, 69]. 
OPEN ISSUES 3: THE QUEST OF NOVEL BIO-
MARKERS  
 We need better markers in many difficult clinical condi-
tions. The vulnerable plaque can be imaged with a variety of 
techniques providing insight into the structural components 
at the basis of its own vulnerability, such as thin fibrous cap 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (7). Risk stratified according to age and gender. The risk is 37% higher in women than in men, and 4-fold higher in children <1 year 
than in adults. The risk is reduced by one-half in elderly (>80 years). Redrawn and modified from ref. 58, on the basis of novel estimates of 
BEIR VII. 
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and high lipid core. Still, we miss a direct imaging of athero-
sclerotic plaque activation, which is in the focus of high-
specificity radiotracers in nuclear medicine and ultrasound 
microbubbles functionalised with specific targeting agents 
binding to endothelial cell receptors expressed by the vulner-
able plaque- although even dumb bubbles may stick over a 
damaged endothelium [70,71]. Nowadays, most of tracers 
aiming at becoming part of an imaging biomarker are based 
on the radiolabelling of biochemical reporting molecules and 
laboratory biomarkers and, although dosimetric issues re-
main a concern for extensive and serial clinical applications, 
this field represents the most promising approach to molecu-
lar and cell imaging. However, non-ionising radiation (NIR) 
imaging, such as optical imaging [72] and MRS and MRI, is 
moving forward to overcome their limitations of in-depth 
penetration and quencing (optical imaging) and sensitivity in 
MRI and MRS. The latter has made a formidable progress by 
exploiting hyperpolarised 13C labelled tracers, such as 13C-
pyruvate to assess myocardial metabolism [73]. The smart 
ligand approach can also be used with CMR. Although we 
can assess and monitor with bioimaging and biochemistry 
markers stable chronic heart failure, we still miss a reliable 
marker of acute heart failure and pulmonary congestion, 
which is different from the hemodynamic congestion cur-
rently measured with invasive or non-invasive approach.  
 Molecular and cellular imaging is a newly emerging field 
in which the modern tools of molecular and cell biology are 
being married to state-of-art technology for noninvasive im-
aging [74]. The approach is ideally suited to assess the effi-
cacy of new treatments which are based on gene and cell 
transfer, for instance to detect in vivo gene-transfer, gene-
uptake, and gene delivery. It can also detect early stages of 
disease, such as endothelial cell activation in early athero-
sclerosis or myocyte apoptosis in early heart failure [74]. 
CONCLUSION 
 Imaging and laboratory biomarkers are an essential sup-
port to modern practice of medicine, allowing a better identi-
fication, severity titration, staging and follow-up of athero-
sclerosis and heart failure disease. Yet, no single perfect 
biomarker exists and there is wide room for optimization and 
integration between clinical evaluation and biomarker 
evaluation. In general, a targeted approach tailored on the 
individual patient should be preferred to a carpet diagnostic 
bombing, which will lead to an exorbitant multiplier of costs, 
risks and further inappropriate testing. The magic “info-
nano-bio” triangle will certainly help to progressively move 
towards cellular and molecular images but all technological 
and methodological innovations should prove their clinical 
added value in the larger framework of sustainability [75]. 
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